AMGEN INC. DL-,0001/ US0311621009 /
11/15/2024 9:57:32 PM | Chg. -12.650 | Volume | Bid10:00:16 PM | Ask10:00:16 PM | Market Capitalization | Dividend Y. | P/E Ratio |
---|---|---|---|---|---|---|---|
268.950EUR | -4.49% | 3,577 Turnover: 971,794.500 |
268.700Bid Size: 37 | 270.300Ask Size: 36 | 144.81 bill.EUR | - | - |
GlobeNewswire
8/29
Great Place To Work Announces the 2024 Best Workplaces in Asia Representing 6.9 Million Employee Exp...
GlobeNewswire
8/28
Prevent Cancer Annual Gala to celebrate three decades of commitment to cancer prevention and early d...
GlobeNewswire
8/15
Alvotech Reports Record Revenues and Adjusted EBITDA for the Second Quarter and First Six Months of ...
GlobeNewswire
8/12
TScan Therapeutics Reports Second Quarter 2024 Financial Results and Provides Corporate Update
GlobeNewswire
8/8
CytomX Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update
GlobeNewswire
8/8
Ardelyx Appoints Experienced Biopharma Executive, Eric Foster, as Chief Commercial Officer
GlobeNewswire
8/5
Avalyn Appoints Erin Lavelle, Seasoned Biopharma Finance Executive, to its Board of Directors
GlobeNewswire
8/1
CytomX Therapeutics to Report Second Quarter 2024 Financial Results on August 8, 2024
GlobeNewswire
7/22
Oxford BioTherapeutics Named Best Tech SME of the Year at Thames Valley Tech & Innovation Awards 202...
GlobeNewswire
7/2
Alvotech Announces Positive Topline Results from Confirmatory Patient Study for AVT03, a Proposed Bi...